SCHEMBL232249

SCHEMBL232249

NNC(=O)c1ccc2cc[nH]c2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.64
HSD17B10 Q99714 2/20 0.64
KDM4E B2RXH2 1/20 0.64
HPGD P15428 1/20 0.64
ENPP2 Q13822 1/20 0.64
TAS1R3 Q7RTX0 1/20 0.61
TAS1R1 Q7RTX1 1/20 0.61
SMYD3 Q9H7B4 3/20 0.58
HDAC1 Q13547 4/20 0.56
HDAC2 Q92769 3/20 0.56
HDAC3 O15379 3/20 0.56
HDAC4 P56524 2/20 0.56
HDAC7 Q8WUI4 2/20 0.56
HDAC10 Q969S8 2/20 0.56
HDAC11 Q96DB2 2/20 0.56
HDAC8 Q9BY41 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
HDAC9 Q9UKV0 2/20 0.56
HDAC5 Q9UQL6 2/20 0.56
ESR1 P03372 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3211677 0.86 F2 (0.57) TAS1R3TAS1R1SMYD3HDAC1HDAC2
SCHEMBL2004886 0.84 KDM4E (0.66) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL26345638 0.83 ALDH1A1 (0.64) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL4102768 0.83 ALDH1A1 (0.64) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL8403078 0.82 TAS1R3 (0.64) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL4164841 0.82 TAS1R3 (0.56) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL50552 0.80 ALDH1A1 (0.70) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL30201702 0.80 ALDH1A1 (0.70) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL14526878 0.79 KDM4E (0.63) ALDH1A1HSD17B10KDM4EHPGDENPP2
SCHEMBL19531859 0.79 TAS1R3 (0.68) ALDH1A1HSD17B10KDM4EHPGDENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559455-B2 Compound as a UBR box domain ligand AUTOTAC INC. (KR) 2026-02-24 US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 US disclosed
WO-2023074936-A1 BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND 주식회사 오토텍바이오 2023-05-04 WO disclosed
EP-4144722-A1 COMPOUND AS UBR BOX DOMAIN LIGAND Autotac Inc. (KR) 2023-03-08 EP disclosed
CN-115715285-A Compounds as UBR box domain ligands 奧土择破利悟 2023-02-24 CN disclosed
US-8778928-B2 Indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use DANPET AB (SE) 2014-07-15 US disclosed
US-20120003153-A1 NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE NEUROSEARCH A/S (DK) 2012-01-05 US disclosed
CN-102300574-A Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use 2011-12-28 CN disclosed
CN-100537568-C 6-substituted pyridoindolone derivatives, their preparation and therapeutic use SANOFI AVENTIS (FR) 2009-09-09 CN disclosed
WO-2005040157-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-05-06 WO disclosed
EP-1183252-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS ASTRAZENECA AB (SE) 2004-02-18 EP disclosed
US-6492406-B1 PROTEIN KINASE C INHIBITORS; ANTIINFLAMMATORY AND IMMUNO-SUPPRESSIVE AGENTS ASTRAZENECA AB (SE) 2002-12-10 US disclosed
EP-1183252-A1 NEW PHARMACEUTICALLY ACTIVE COMPOUNDS AstraZeneca AB (SE) 2002-03-06 EP disclosed
WO-2000071537-A1 NEW PHARMACEUTICALLY ACTIVE COMPOUNDS ASTRAZENECA AB (SE) 2000-11-30 WO disclosed
CN-1056144-C 6-heterocyclic-4-amino1,3,4,5-tetrahydrobenz{CD}indoles for treating motion sickness and vomiting LILLY CO ELI (US) 2000-09-06 CN disclosed
US-5750554-A COMPOUNDS FOR TREATMENT OF ANXIETY, DEPRESSION, ANTISECRETORY AGENTS, HYPOTENSIVE AGENTS AND TREATMENT OF EATING PROBLEMS ELI LILLY AND COMPANY (US) 1998-05-12 US disclosed
US-5736562-A MODIFY FUNCTION OF SEROTONIN IN MAMMALS ELI LILLY AND COMPANY (US) 1998-04-07 US disclosed
US-5674884-A FOR TREATMENT OF SEROTONIN-RELATED DISORDERS ELI LILLY AND COMPANY (US) 1997-10-07 US disclosed
CN-1094724-A 6-heterocycle-4-the amino-1,3,4 that is used for the treatment of motion sickness and vomiting sickness, 5-tetrahydro benzo [cd] indoles LILLY CO ELI (US) 1994-11-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF ALDH1A1 2317/4885HSD17B10 1933/4885KDM4E 1340/4885
US-12559455-B2 Compound as a UBR box domain ligand UBR4, UBTF, UBQLN1 ALDH1A1 1486/4885HSD17B10 1707/4885KDM4E 707/4885
US-20120003153-A1 NOVEL INDOLYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL AND DIAGNOSTICAL USE CHRNA6, CHRNA10, CHRNA3 ALDH1A1 1114/4885HSD17B10 1143/4885KDM4E 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.